Medical Research Council Technology
This article was originally published in Start Up
Britain's Medical Research Council has done a lot over the last decade to develop its technology transfer activities. Almost half of the 16 spin-off companies based on MRC research have appeared in the last two years. One important catalyst for this increase in spin-out activity was the founding in 1998 of a venture capital fund with priority access to companies based on MRC-owned technology, the UK Medical Ventures Fund/MVM Ltd. More recently, the creation of Medical Research Council Technology, bringing together three geographically distinct units involved in technology transfer, has led to a simpler, more efficient structure and better staff retention.
You may also be interested in...
The Wellcome Trust has initiated a new approach to helping accelerate the transformation of scientific research into useful medicines. Through its University Translation Awards and Strategic Translation Awards, the Trust hopes to encourage collaboration between university researchers and tech transfer operations, fill funding and support gaps as they arise, and back high potential, targeted projects that may otherwise have difficulty finding finance.
Two years ago, the UK's publicly-funded Medical Research Council set up a new venture fund with a right of first refusal to all MRC-funded technology. Its British VC competitors greeted the newcomer, which claimed to want to fill a gap in seed-stage investing, coolly--they felt that no such gap existed and that UK Medical Ventures Fund would have an unfair advantage. Whether they're still jealous is uncertain, but they are doing deals with the new fund, which has significantly stepped up the rate at which MRC technology is transferred to the marketplace.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.